Evidence map›Paper›PMID 32923126›Full record

ArticleOncoimmunology2020

A rationally-engineered IL-2 improves the antitumor effect of anti-CD20 therapy.

Ana Victoria Casadesús, Claire Deligne, Béré Kadjdiatou Diallo, Katya Sosa, Nathalie Josseaume, Circe Mesa, Kalet León, Tays Hernández, Jean-Luc Teillaud

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Oncoimmunology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.2field-weighted citation impact, top 52% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 2 citations in OpenAlex.

  1. Orchestration of Tumor-Associated Macrophages in the Tumor Cell-Macrophage-CD8International journal of biological sciences · 2025
    Review
  2. Review
  3. Article
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 4 institutions in 3 countries.

Ana Victoria CasadesúsDepartment of Chimeric Proteins, Immunobiology Division, Center of Molecular Immunology (CIM), Havana, Cuba.
Claire DeligneThe Kennedy Institute of Rheumatology, University of Oxford, Oxford, UK.
Béré Kadjdiatou DialloSorbonne Université, Faculté De Médecine, UMRS 1135, Centre d'Immunologie Et Des Maladies Infectieuses Paris (Cimi-paris), Paris, France.
Katya SosaDepartment of Chimeric Proteins, Immunobiology Division, Center of Molecular Immunology (CIM), Havana, Cuba.
Nathalie JosseaumeInserm U.1138, Cordeliers Research Center, Paris, France.
Circe MesaImmunobiology Division, Center of Molecular Immunology (CIM), Havana, Cuba.
Kalet LeónSystems Biology Department, Center of Molecular Immunology, Havana, Cuba.
Tays HernándezDepartment of Chimeric Proteins, Immunobiology Division, Center of Molecular Immunology (CIM), Havana, Cuba.
Jean-Luc TeillaudSorbonne Université, Faculté De Médecine, UMRS 1135, Centre d'Immunologie Et Des Maladies Infectieuses Paris (Cimi-paris), Paris, France.ORCID 0000-0003-4442-9565
Center of Molecular Immunology (Cuba) · CUInserm · FRDélégation Paris 5 · FRUniversity of Oxford · GB

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Anti-CD20 treatment represents a therapeutic benefit for patients with B-cell lymphomas, although more efficient therapies are needed for refractory or relapsing patients. Among them, the combination of anti-CD20 and IL-2 that induces T cell response has been hampered by the expansion of FoxP3

Indexed as

CD8-Positive T-LymphocytesInterleukin-2AnimalsFemaleHumansMiceRituximabInterleukin-2RituximabAnti-CD20IL-2IL-2 muteinimmunotherapylymphoma

Identifiers

PMID32923126
PMCPMC7458652
OpenAlexW3033391229

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.